Currently, some combination therapies including TKIs, such as lenvatinib or apatinib, with an ICB agent have shown benefits for patients with advanced HCC.[16, 17] However, combination treatment with an anti‐PD‐1 antibody and sorafenib failed in mouse model experiments and showed no additional antitumor activity.[9] A high‐profile phase III clinical trial of lenvatinib combined with an anti‐PD‐1 antibody (NCT03713593) failed to meet the primary endpoints for OS and progression‐free survival. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.